Skip to main content
. 2024 Jul 8;8:e2400143. doi: 10.1200/PO.24.00143

FIG 1.

FIG 1.

Oncoplot of pathogenic variants, previous therapies, and cytopenias among patients with variants detected with VAF ≥2%. The overall prevalence of CH was 35%. One patient did not receive PRRT, and therefore, cytopenia could not be evaluated during treatment (indicated by X). Variants with VAF ≥2% were considered CH. PRRT, peptide receptor radionuclide therapy.